Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10(a)    
    

[SUTHERLAND
ASBILL & BRENNAN LLP LETTERHEAD] 

	

DAVID S. GOLDSTEIN

DIRECT LINE: 202.383.0606

Internet: david.goldstein@sablaw.com	
 	

 

April 30,
2004 

Board
of Directors

Protective Life Insurance Company

2801 Highway 201 South

Birmingham, Alabama 35223 

Directors:

        We
hereby consent to the reference to our name under the caption "Legal Matters" in the statement of additional information filed as part of post-effective amendment number 7
to the registration statement on Form N-4 (File No. 333-94047) filed by Protective Life Insurance Company and Protective Variable Annuity Separate Account with
the
Securities and Exchange Commission. In giving this consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act of 1933. 

	 	 	Sincerely,
	

 	
 	

SUTHERLAND ASBILL & BRENNAN LLP
	

 	
 	

By:	

/s/  DAVID S. GOLDSTEIN      
 David S. Goldstein

QuickLinks

Exhibit 10(a)QuickLinks
 -- Click here to rapidly navigate through this document

Exhibit 10(b)  

 
 

Consent of Independent Accountants    
    

        We hereby consent to the use in this Registration Statement on Form N-4 (File No. 333-94047) of our report dated
March 11, 2004, relating to the consolidated financial statements and financial statement schedules of Protective Life Insurance Company and Subsidiaries, which appears in such Registration
Statement. We also consent to the use in this Registration Statement of our report dated April 15, 2004, relating to the financial statements of The Protective Variable Annuity Separate
Account, which appears in such Registration Statement. We also consent to the reference to us under the heading "Independent Accountants" in such Registration Statement. 

PricewaterhouseCoopers
LLP 

Birmingham,
Alabama

April 30, 2004 

QuickLinks

Consent of Independent AccountantsQuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10(a)    
    

[SUTHERLAND
ASBILL & BRENNAN LLP LETTERHEAD] 

	

DAVID S. GOLDSTEIN

DIRECT LINE: 202.383.0606

Internet: david.goldstein@sablaw.com	
 	

 

April 30,
2004 

Board
of Directors

Protective Life Insurance Company

2801 Highway 201 South

Birmingham, Alabama 35223 

Directors:

        We
hereby consent to the reference to our name under the caption "Legal Matters" in the statement of additional information filed as part of post-effective amendment number
10 to the registration statement on Form N-4 (File No. 333-68551) filed by Protective Life Insurance Company and Protective Variable Annuity Separate Account with
the
Securities and Exchange Commission. In giving this consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act of 1933. 

	 	 	Sincerely,
	

 	
 	

SUTHERLAND ASBILL & BRENNAN LLP
	

 	
 	

By:	

/s/  DAVID S. GOLDSTEIN      
 David S. Goldstein

QuickLinks

Exhibit 10(a)QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10(b)    
    

 
 

Consent of Independent Accountants    
    

        We hereby consent to the use in this Registration Statement on Form N-4 (File No. 333-68551) of our report dated March 11, 2004, relating to the consolidated
financial statements and financial statement schedules of Protective Life Insurance Company and Subsidiaries, which appears in such Registration Statement. We also consent to the use in this
Registration Statement of our report dated April 15, 2004, relating to the financial statements of The Protective Variable Annuity Separate Account, which appears in such Registration Statement. We
also consent to the reference to us under the heading "Independent Accountants" in such Registration Statement. 

	 	PricewaterhouseCoopers LLP

Birmingham, Alabama

April 30, 2004 

QuickLinks

Exhibit 10(b)

Consent of Independent AccountantsQuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.519    
    

 
 

CHIRON CORPORATION
  CORPORATE GOVERNANCE GUIDELINES    
    

 
 

INTRODUCTION    
    

        The Board of Directors of Chiron Corporation ("Chiron") is elected by the stockholders of Chiron to serve their interests through oversight of management and
Chiron's business. The primary responsibility of the directors is to exercise their business judgment in the best interests of Chiron and its stockholders. The Board, acting on the recommendation of
its Nominating and Corporate Governance Committee, has developed and adopted these corporate governance principles (the "Guidelines") to promote the functioning of the Board and its committees, to
promote the interests of stockholders and to set forth a common set of expectations as to how the Board, its various committees and individual directors should perform their functions. Chiron is party
to a Governance Agreement, dated as of November 20, 1994, with Novartis AG ("Novartis"), as amended (as it may be further amended from time to time, the "Governance Agreement") and these
guidelines have been developed in light of, among other things, that agreement. 

 
 

BOARD COMPOSITION    
    

        The composition of the Board should balance the following goals: 

	•
	The
size of the Board should facilitate substantive discussions of the whole Board in which each director can participate meaningfully;

	•
	The
composition of the Board should encompass a broad range of skills, expertise, industry knowledge, diversity of opinion and contacts relevant to Chiron's business;

	•
	The
composition of the Board shall reflect the requirements of the Governance Agreement;

	•
	A
substantial majority of the Board shall consist of directors who are neither officers or employees of Chiron or its subsidiaries nor have a relationship which, in the
opinion of the Board, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director, and who are otherwise "independent" under the rules of the Nasdaq
Stock Market, Inc. 

 
 

SELECTION OF CHAIRPERSON OF THE BOARD AND CHIEF EXECUTIVE OFFICER    
    

        The Board is free to select its Chairperson and Chiron's Chief Executive Officer (the "CEO") in the manner it considers in the best interests of Chiron at any
given point in time. These positions may be filled by one individual or by two different individuals. 

 
 

SELECTION OF DIRECTORS    
    

        Nominations.    Subject to the Governance Agreement and the right of Novartis to designate a specific number of the members of
the Board pursuant thereto, the Nominating and Corporate Governance Committee is responsible for determining the slate of director nominees for election to Chiron's Board of Directors and the
individuals to fill vacancies occurring between annual meetings of stockholders. 

        Criteria.    The Nominating and Corporate Governance Committee shall determine new nominees for the position of independent
director who satisfy the requirements of the Nasdaq Stock Market, Inc., the Governance Agreement and the following criteria: 

	•
	Personal
qualities and characteristics, accomplishments and reputation in the business community; 

 

	•
	Current
knowledge and contacts in the communities in which Chiron does business and in Chiron's industry or other industries relevant to Chiron's business;

	•
	Ability
and willingness to commit adequate time to Board and committee matters;

	•
	The
fit of the individual's skills and personality with those of other directors and potential directors in building a Board that is effective, collegial and responsive to
the needs of Chiron; and

	•
	Diversity
of viewpoints, background, experience and other factors. 

        Invitation.    The invitation to join the Board should be extended by the Board itself via the Chairperson of the Board and CEO
of Chiron, together with an independent director, when deemed appropriate. 

        Orientation and Continuing Education.    Management, working with the Board, will provide an orientation process for new
directors, including background material on Chiron, its business plan and its risk profile, and meetings with senior management. Periodically, management should prepare additional educational sessions
for directors on matters relevant to Chiron, its business plan and risk profile. 

 
 

ELECTION TERM    
    

        The Board does not believe it should establish term limits. 

 
 

RETIREMENT OF DIRECTORS    
    

        The Board does not believe it should establish a mandatory retirement age. In determining the slate of director nominees to stand for election or in filling any
vacancy, the Nominating and Corporate Governance Committee will consider the age of each nominee among all other relevant factors. 

 
 

BOARD MEETINGS    
    

        The Board currently plans four meetings each year, with further meetings to occur (or action to be taken by unanimous consent) at the discretion of the Board. The
meetings will usually consist of committee meetings and the Board meeting, extended over two or three days. 

        The
agenda for each Board meeting will be determined by the Board Chair in consultation with the Chief Executive Officer. The agenda will be prepared by the Corporate Secretary.
Management will seek to provide to all directors an agenda and appropriate materials in advance of meetings, although the Board recognizes that this will not always be consistent with the timing of
transactions and the operations of the business and that in certain cases it may not be possible. 

 
 

EXECUTIVE SESSIONS    
    

        All non-management directors will have four regularly scheduled meetings each year, at which only non-management directors are present. In
addition, to ensure free and open discussion and communication among the independent directors of the Board, the independent directors will have two regularly scheduled executive sessions each year,
and more frequently as necessary or desirable, in conjunction with regularly scheduled meetings of the Board. The non-management and independent directors shall designate a presiding
director to preside at their executive sessions. The presiding director shall establish the agenda for each of these meetings and may invite additional participants as appropriate. 

2

 

 
 

THE COMMITTEES OF THE BOARD    
    

        Chiron shall have at least the committees required by the rules of the Nasdaq Stock Market, Inc. and the Governance Agreement. Except to the extent that
the Board has delegated or delegates in the future its authority to a committee, all power and authority of the Board is reserved by the Board to itself. Currently, Chiron's committees consist of the
Audit Committee, the Compensation Committee, a nominating committee, which at Chiron is called the Nominating and Corporate Governance Committee, the Stock Option Plan Administration Committee, the
Finance Committee and, as may be required from time to time under the terms of the Governance Agreement, a Strategic Planning Committee. 

        The
Chair of each Committee shall set the agenda for meetings of his or her Committee. All directors, whether members of a committee or not, are invited to make suggestions to a
committee chair for additions to the agenda of his or her committee or to request that an item from a committee agenda be considered by the Board. Each committee chair will give a periodic report of
his or her committee's activities to the Board. 

        Each
of the Nominating and Corporate Governance Committee, the Audit Committee and the Compensation Committee shall be composed of directors who are not officers or employees of Chiron
or its subsidiaries or any other individual having a relationship which, in the opinion of the Board, would interfere with the exercise of independent judgment in carrying out the responsibilities of
a director, and who are otherwise "independent" and qualified to serve as a member of such committee under applicable law and under the rules of the Nasdaq Stock Market, Inc. The required
qualifications for the members of each committee shall be set out in the respective committees' charters. A director may serve on more than one committee for which he or she qualifies. 

 
 

MANAGEMENT DEVELOPMENT AND CEO SUCCESSION    
    

        At least annually, the Board shall review and concur in a succession plan, developed by management, addressing the policies and principles for selecting a
successor to the CEO, both in an emergency situation and in the ordinary course of business. The succession plan should include an assessment of the experience, performance, skills and planned career
paths for possible successors to the CEO. The Board shall receive and review at least annually reports from the CEO regarding senior management development. 

 
 

TRANSACTIONS WITH NOVARTIS    
    

        The Governance Agreement governs certain aspects of the relationship between Chiron and Novartis. Among other things, under the Governance Agreement, Chiron will
not enter into specified agreements or transactions with Novartis without first obtaining the approval of the Independent Directors (as defined in the Governance Agreement) or requisite stockholder
approval. Such governance principles of the Governance Agreement will be considered to be incorporated in, and a part of, these guidelines. 

 
 

BOARD COMPENSATION    
    

        The Compensation Committee shall review periodically and not less frequently than every three years, and report to the Board with its recommendations regarding,
the components and amount of Board compensation, including its evaluation of compensation of boards of similarly situated companies. In order to align the interests of directors and stockholders, the
Board believes that directors should receive a significant part of their on-going compensation in the form of equity in Chiron. Such equity compensation should consist of restricted share
rights which entitle directors to receive shares of Chiron common stock only upon cessation of service on the Board. The Board believes that such restricted share rights, by requiring directors to
maintain an ownership interest in 

3

 

Chiron
throughout the directors' tenure, will firmly align directors' interests with the long-term interests of Chiron's stockholders. The Board also intends to continue to use stock
option grants in order to attract leading candidates to serve on the Board, but a significant portion of the stock issued to directors upon exercise of options should be subject to certain
restrictions on transfer to further align the directors' interests with the long-term interests of stockholders. 

 
 

EXPECTATIONS OF DIRECTORS    
    

        The business and affairs of Chiron shall be managed by or under the direction of the Board in accordance with Delaware law. In performing their duties, the
primary responsibility of the directors is to exercise their business judgment in the best interests of Chiron and its stockholders. The Board has developed a number of specific expectations of
directors to promote the discharge of this responsibility and the efficient conduct of the Board's business. 

        Commitment and Attendance.    All directors should make all reasonable efforts to attend meetings of the Board and meetings of
committees of which they are members. Members may attend by telephone or video conference (when available) to mitigate conflicts. 

        Participation in Meetings.    Each director should be sufficiently familiar with the business of Chiron, including its financial
statements and capital structure, and the risks and competition it faces, to facilitate active and effective participation in the deliberations of the Board and of each committee on which he or she
serves. Upon request, management will make appropriate personnel available to answer any questions a director may have about any aspect of Chiron's business. Directors should review the materials
provided by management and advisors in advance of the meetings of the Board and its committees and should arrive prepared to discuss the issues presented. 

        Loyalty and Ethics.    In their roles as directors, all directors owe a duty of loyalty to Chiron. This duty of loyalty mandates
that the interests of Chiron take precedence over any interests possessed by a director. 

        Chiron
has adopted a Board of Directors Procedure Re: Conflicts of Interest (the "Procedure"), and a Code of Conduct (the "Code"), which includes a compliance program for enforcement.
Both the Procedure and the Code deal with activities of directors, particularly with respect to potential conflicts of interest and the taking of corporate opportunities for personal use. The
Procedure provides, among other things, that conflicts of interest or potential conflicts of interest concerning a director or the CEO are to be reported to the Nominating and Corporate Governance
Committee. Directors should be familiar with the Procedure's and the Code's provisions in these areas and should consult with Chiron's counsel in the event of any issues. 

        Other Directorships.    Chiron values the experience directors bring from other boards on which they serve, but recognizes that
those boards may also present demands on a director's time and availability and may present conflicts or legal issues. Directors should advise the chairperson of the Nominating and Corporate
Governance Committee and the CEO before accepting membership on other boards of directors or other significant commitments involving affiliation with other businesses or governmental units. 

        Contact with Management.    All directors are invited to contact the CEO at any time to discuss any aspect of Chiron's business.
Directors also have complete access to other members of management. The Board expects that there will be frequent opportunities for directors to meet with the CEO and other members of management in
Board and committee meetings and in other formal or informal settings. 

        Further,
the Board encourages management to, from time to time, bring managers into Board meetings who: (a) can provide additional insight into the items being discussed because
of personal 

4

 

involvement
and substantial knowledge in those areas, and/or (b) are managers with future potential that the senior management believes should be given exposure to the Board. 

        Contact with Other Constituencies.    It is important that Chiron speak to employees and outside constituencies with a single
voice, and that management serve as the primary spokesperson. 

        Confidentiality.    The proceedings and deliberations of the Board and its committees are confidential. Each director shall
maintain the confidentiality of information received in connection with his or her service as a director. 

 
 

EVALUATING BOARD PERFORMANCE    
    

        The Board, acting through the Nominating and Corporate Governance Committee, should conduct a self-evaluation at least annually to determine whether
it is functioning effectively. The Nominating and Corporate Governance Committee should periodically consider the mix of skills and experience that directors bring to the Board to assess whether the
Board has the necessary tools to perform its oversight function effectively. 

        Each
committee of the Board should conduct a self-evaluation at least annually and report the results to the Board. Each committee's evaluation must compare the performance
of the committee with the requirements of its written charter, if any. 

 
 

RELIANCE ON MANAGEMENT AND OUTSIDE ADVICE    
    

        In performing its functions, the Board is entitled to rely on the advice, reports and opinions of management, counsel, accountants, auditors and other expert
advisors. The Board shall have the authority to retain and approve the fees and retention terms of its outside advisors. 

5

QuickLinks

Exhibit 10.519

CHIRON CORPORATION CORPORATE GOVERNANCE GUIDELINES

INTRODUCTION

BOARD COMPOSITION

SELECTION OF CHAIRPERSON OF THE BOARD AND CHIEF EXECUTIVE OFFICER

SELECTION OF DIRECTORS

ELECTION TERM

RETIREMENT OF DIRECTORS

BOARD MEETINGS

EXECUTIVE SESSIONS

THE COMMITTEES OF THE BOARD

MANAGEMENT DEVELOPMENT AND CEO SUCCESSION

TRANSACTIONS WITH NOVARTIS

BOARD COMPENSATION

EXPECTATIONS OF DIRECTORS

EVALUATING BOARD PERFORMANCE

RELIANCE ON MANAGEMENT AND OUTSIDE ADVICE

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00065-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00065-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00065-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00065-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00065-of-00352.parquet"}]]